About This Publication:

  • Print This Page
  • Text a Friend
  • Subscribe to an RSS Feed

Sample Content 


Sign up to stay informed--receive email notifications for this journal

Cellular Reprogramming

Editor-in-Chief: Professor Sir Ian Wilmut, OBE FRS FRSE

ISSN: 2152-4971 • Published Bimonthly • Online ISSN: 2152-4998

Current Volume: 16

Latest Impact Factor* is 2.345

*2013 Journal Citation Reports® published by Thomson Reuters, 2014

For Authors

  • Manuscript Submissions
  • NIH/HHMI Wellcome Trust Policies
  • Self-Archiving Policy
  • Open Access Policy
  • Manuscript Submissions

    We invite all authors to submit online any new manuscripts that are to be considered for publication. Please use the following URL:


    For further information or questions about articles in the peer-review process, please contact Jane Taylor at jane.taylor@ed.ac.uk

    For technical information on using Manuscript Central, contact Patricia Meravy at
    (914) 740-2132; or PMeravy@liebertpub.com.

    Instructions for Authors

    Cellular Reprogramming is a peer-reviewed journal that publishes original research articles, review papers, and short communications. Contributions are welcome in the fields of oocyte maturation, activation, fusion, cell cycle, gene expression, embryo culture, and embryo transfer as it relates to nuclear transfer; embryonic stem cells, primordial germ cells, and somatic cell lines, including their genetic modification (as it relates to nuclear transfer); and production of pharmaceutical proteins in milk by cloning, and tissue and organ therapy (xenotransplantation) using cloned animals and germ line gene therapy.

    The Journal will also publish LiteratureWatches, Web-Watches, Point/Counterpoints, News and Comments, including Meetings, and Book Reviews. 

    Manuscripts submitted to this Journal must not be under consideration elsewhere and must not have been previously published.


    Preparation of Manuscript


    All submitted manuscripts will be processed through plagiarism detection software.  Plagiarized manuscripts will be rejected immediately.

    Animal Ethics

    The editor acknowledges that all animals are creatures of great value and remarkable complexity. The use of animals in research can contribute uniquely to the advancement of scientific knowledge, and thus, ultimately, to improvements in human health or welfare of humans and animals. Please include in your manuscript a description of the regulatory framework that monitored the animal welfare in your institution.

    Research Papers

    Manuscripts should be submitted double-spaced in Microsoft Word. Leave ample margins on both sides, top and bottom.

    When uploading your paper be prepared to enter:

    • A running title of 45 characters maximum including spaces.
    • Supply an abstract of about 200 words, stating the aims, results, and conclusions drawn from the study. Reference citations are not permitted in the abstract.
    • Your submission should display the following in this order: Introduction, Materials and Methods, Results, Discussion, Acknowledgments, References, Author Disclosures, and the tables and figure legends. Results and Discussion should be separate sections.
    • Authors should review the style and clarity of their manuscripts with colleagues before submission.

    Please follow the protocol described herein to avoid delay in publication. Authors should note that manuscripts may be edited if needed to ensure clear grammatical English usage. The editors welcome suggestions concerning potential reviewers.

    Brief Reports

    Submission of Brief Reports is also welcome. A Brief Report should communicate new methodological information in the fields of mammalian cloning, transgenics, and cell and tissue therapy. It should be divided as follows: Abstract  (no more than 200 words), Introduction, Materials and Methods, Results, Discussion (please note that in Brief Reports, Results and Discussion can be combined), Acknowledgments, Disclosures, References, and tables and figure legends.

    The whole report should be composed of no more than four journal pages (about 3,000 words), including tables and figures. For general rules, please follow the guidelines given for Research Articles.

    Tables and Illustrations

    Use Arabic numerals to number tables. Do not repeat information that is given in the text, and do not make a table for data that can be given in the text in one or two sentences. Explain abbreviations used in the body of the table in footnotes. If the table is taken from a copyrighted publication, credit must be given in a footnote.

    A legend should be supplied for each illustration, and all legends should be typed (double-spaced) and numbered consecutively at the end of the manuscript. Figures should be numbered in the order cited in the text. Images should not show the name of a manufacturer.

    Please follow these guidelines when submitting figures:

      • Do not include any illustrations as part of your text file.
      • Do not prepare any figures in Word as they are not workable.
      • Line illustrations must be submitted at  900 DPI.
      • Halftones and color images should be submitted at a minimum of 300 DPI.
      • Adobe is the preferred software. 
      • PowerPoint and Excel files cannot be uploaded.
      • Save art as either TIFFor EPS files. Avoid submitting JPEG files.
      • Color art must be saved as CYMK not RGB.


    All authors are expected to disclose any institutional or commercial affiliations that might pose a conflict of interest regarding the publication of a manuscript. Institutional affiliations, as indicated on the title page, should include all corporate affiliations and any funding sources that support the work. Other types of affiliation, including consultantships, honoraria, stock ownership, equity interests, arrangements regarding patents, or other vested interests should be disclosed in the Disclosure section.


    All references should be cited by authors and dates within the text (citations are not permitted in the abstract):

        i.e. The ribosomal RNA (rrn) operons in E. coli contain single copies of each of the 16S, 23S, and 5S r(RNA) genes (Pace, 1973).

    If more than two authors are involved, use et al. after the first author’s name:
        i.e. (Wells, et al., 1997).

    If several article by the same authors are cited in one sentence, use a lower case letter designation to indicate the individual papers:

        i.e. (Dunn and Studier, 1973a, 1973b). Use same designation in reference list.

    All references in the bibliography should be double spaced and listed in alphabetical order at the end of the paper. References should include the complete titles of cited papers and all authors:

    Journal citation: Pace, N. (1973). Structure and synthesis of the ribosomal ribonucleic acid of prokaryotes. Bacteriol. Rev. 37, 562–603.

    Book citation: Brosius, J. (1987). Expression vectors employing l, trp, lac, and lpp-derived promoters. In Vectors, a Survey of Molecular Cloning Vectors and Their Uses. R.L. Rodriguez and D.T. Denhardt, eds. (Butterworth Publishers, Stoneham, MA) pp. 205–225.

    When data from an unpublished source are given, supply the researcher’s name. If the work is in press, give the journal in which it is to be published or the name of the publisher. Abbreviations of journal names should follow the style of MEDLINE.


    The author must obtain permission whenever it is required in conjunction with the reproduction of material such as figures and tables from copyrighted material. Written permission must be obtained from the publisher of the journal or book concerned. The publication from which the figure or table is taken must be listed in the reference list. Finally, a footnote of a reprinted table, or of the legend of a reprinted figure, should read “reprinted by permission from Jones et al.” and list the appropriate reference. All permissions listings must be shown in the manuscript—they cannot be entered on proofs. 


    Reprints may be ordered by following the special instructions that will accompany page proofs, and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher. Reprints ordered after an issue is printed will be charged at a substantially higher rate.


    The Journal is published by Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801-5215. Telephone: (914) 740-2100; fax: (914) 740-2101; e-mail: info@liebertpub.com  on-line: www.liebertpub.com

  • NIH/HHMI Wellcome Trust Policies

    NIH Public Access Policy: In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final accepted paper (after copy-editing and proofreading) to PubMed Central (PMC) on behalf of the authors. Authors need not take any action. The manuscript's public access posting on PMC will occur 12 months after final publication. This service is provided free of charge. Please note that authors may not deposit manuscripts directly to PMC or other sites without permission from Mary Ann Liebert, Inc.

  • Self-Archiving Policy

    Mary Ann Liebert, Inc. is a "blue" publisher (as defined by Sherpa), as we allow self-archiving of post-print (ie final draft post-refereeing) or publisher's version/PDF.

    In assigning Mary Ann Liebert, Inc. copyright, the author retains the right to deposit such a 'post-print' on their own website, or on their institution's intranet, or within the Institutional Repository of their institution or company of employment, on the following condition, and with the following acknowledgement:

    This is a copy of an article published in the [JOURNAL TITLE] © [year of publication] [copyright Mary Ann Liebert, Inc.]; [JOURNAL TITLE] is available online at: http://online.liebertpub.com.

    Authors may also deposit this version on his/her funder's or funder's designated repository at the funder's request or as a result of a legal obligation, provided it is not made publicly available until 12 months after official publication.

  • Open Access Policy

    Choose Liebert Open Access Option!

    Ensure maximum visibility, discoverability, and impact for your article with our Liebert Open Access (OA) Option.

    Your investment guarantees:

    • Immediate, unrestricted global access in 170 countries
    • Maximum visibility for increased readers, citations, and downloads
    • Targeted email announcement highlighting your article to thousands of thought-leaders in your field
    • Rapid, rigorous peer-review and editorial attention
    • Fast Track online-ahead-of-print publication
    • Immediate upload to PubMed Central and other internationally recognized repositories*
    • Recognition on online Table of Contents with exclusive OA icon
    • Compliance with OA funding mandates with no embargo period
    • Savings on future OA article publication
    • Complimentary membership in AuthorCite®, the author services platform exclusively licensed by Mary Ann Liebert, Inc. that delivers the tools you need to maximize your professional impact.

    These valuable benefits are included with a one-time article processing charge (APC). APC charge varies based on journal, membership, and subsequent submissions.

    Contact openaccess@liebertpub.com for questions on article Open Access options. 

     *Please note that PubMedCentral, not the Publisher, has sole control over when the paper is made live on PMC.


    Is your Institution a member of the Liebert Author Advocacy Program?

    The Liebert Author Advocacy Program (LAAP) provides valuable membership benefits for OA publication to institutional and funding organizations, and supports global funding mandates.  Authors who are affiliated with LAAP member institutions receive all the valuable benefits of Liebert OA article publication, and more.

    For details, and to recommend institutional membership visit: www.authoradvocacy.com or contact laap@liebertpub.com 




Recommended Publications

You may be interested in the following publications:

    Stem Cells and Development

    Stem Cells and Development

    Globally recognized as the trusted source for critical, even controversial coverage of emerging hypotheses and novel findings on stem cells of all tissue types and their potential therapeutic applications.

    Tissue Engineering, Parts A, B, & C

    Tissue Engineering, Parts A, B, & C

    The preeminent, biomedical journal bringing together the principles of engineering and life sciences to advance the field with cutting-edge research and applications on all aspects of tissue growth and regeneration.

    Rejuvenation Research

    Rejuvenation Research

    Key explorations and cutting-edge advancements on the molecular and cellular mechanisms that may ultimately contribute to slowing or reversing the aging process.

    DNA and Cell Biology

    DNA and Cell Biology

    Combining mechanistic and clinical studies from multiple systems in a single resource, the Journal delivers authoritative, peer-reviewed reporting on the latest research in the field of molecular biology.

Browse All Publications »